Addus HomeCare Corporation

---

source: coverage-next-full ticker: ADUS step: 01 title: Business Overview & Value Chain generated: 2026-05-27

Step 01 — Business Overview & Value Chain: Addus HomeCare Corporation (ADUS)

1. Business Description

Addus HomeCare Corporation is a Frisco, Texas-based provider of home- and community-based services, operating three distinct segments that collectively serve patients across 21+ states. [S1] Founded in 1979 and public since 2009, the company has evolved from a primarily Illinois-based personal care agency into one of the largest independent multi-state home care platforms in the United States.

Core Mission: Enable medically complex and functionally limited individuals — predominantly elderly Medicaid/Medicare "dual eligibles" — to receive care in their homes rather than in higher-cost institutional settings (nursing homes, hospitals).

FY2025 Revenue by Segment:

Segment	Revenue	% of Total	Key Payor
Personal Care	~$1,100M est.	~77%	Medicaid / HCBS / MCOs
Hospice	~$213M est.	~15%	Medicare / Medicaid
Home Health	~$110M est.	~8%	Medicare / MCOs
Total	$1,423M	100%

[S1: 10-K FY2025, Q1 2026 8-K]

2. Three-Segment Business Model

Segment 1: Personal Care (Core Business, ~77% of Revenue)

• Service: Non-medical assistance with activities of daily living (ADLs): bathing, dressing, grooming, mobility assistance, light housekeeping, meal preparation, companionship
• Consumers: Predominantly elderly, disabled, or functionally limited individuals with Medicaid eligibility; heavily "dual eligible" (Medicare + Medicaid)
• Employees: Personal Care Aides (PCAs), Home Health Aides (HHAs) — paraprofessional, typically hourly, no clinical license required
• Payor: State Medicaid agencies directly, and increasingly Medicaid Managed Care Organizations (MCOs) that have assumed HCBS risk from states
• Revenue model: Hours of service delivered × contracted hourly rate (set by state or MCO contract)
• Key geographies (FY2025): Illinois (historic core, ~30-35% est.), Texas (expanded via Gentiva acquisition), Indiana, Ohio, Missouri, and 15+ other states

Segment 2: Hospice (~15% of Revenue)

• Service: End-of-life care for terminally ill patients (typically prognosis of ≤6 months); includes pain management, spiritual support, family counseling
• Employees: Registered nurses, social workers, chaplains, hospice aides — multidisciplinary team model
• Payor: Medicare Hospice Benefit (primary), Medicaid
• Revenue model: Per-diem rate × days enrolled (4 levels of care: routine home care, continuous home care, general inpatient, respite)
• Regulatory note: Medicare sets national per-diem rates; hospice election reduces other Medicare spending creating value for the payer

Segment 3: Home Health (~8% of Revenue)

• Service: Skilled nursing, physical therapy, occupational therapy, speech therapy — post-acute or chronic disease management
• Employees: Registered nurses, licensed physical/occupational/speech therapists
• Payor: Medicare, Medicare Advantage (MCOs), Medicaid
• Revenue model: Per-episode (PDGM under Medicare) or per-visit
• Dynamics: Subject to Medicare rate cuts; ADUS home health has been the softest segment in recent quarters [S2]

3. Value Chain Layer Map

UPSTREAM (Referral & Contract)
├── State Medicaid Agencies → set HCBS rates, award contracts
├── Medicaid MCOs → negotiate per-member-per-month or hourly rates
├── Medicare → set hospice per-diems (national) + home health PDGM rates
├── Hospitals / SNFs / ACOs → discharge planning, referral source for home health + hospice
└── Physicians / Palliative Care teams → hospice order, home health order

MIDSTREAM (ADUS Operations)
├── Central Services: HR, recruitment, training, compliance, EVV technology
├── Branch Operations: ~250+ care centers across 21+ states
├── Caregiver Workforce: ~50,000+ personal care aides + clinical staff
├── Care Coordination: matching patients to caregivers, scheduling, quality monitoring
└── Billing & Collections: claims submission to state agencies/MCOs/Medicare

DOWNSTREAM (Consumer)
└── Patient/Consumer: elderly, dual-eligible, disabled individual at home
    ├── Outcome: avoid nursing home placement, reduce hospitalizations
    └── Value: ~60-80% cost reduction vs. institutional care

4. Revenue Architecture (Unit Economics)

Personal Care Unit Economics:

• Revenue per hour: $20-25 (set by state Medicaid / MCO contracts; varies significantly by state)
• Caregiver wage: $15-19/hr (varies by state; minimum wage floors increasingly binding)
• Direct cost ratio: ~67% of revenue (caregiver wages + benefits + workers' comp)
• Gross margin: ~33% (net of caregiver costs)
• SG&A: ~23% of revenue (branch overhead, compliance, corporate)
• EBITDA margin: ~10-11%

Hospice Unit Economics:

• Average daily census: Growing; hospice per-diem from Medicare (FY2025 routine rate ~$228/day)
• ADUS hospice: Higher-margin segment than personal care (Medicare rates historically more stable)

Home Health Unit Economics:

• PDGM: 60-day episode payment varying by diagnosis + functional status; Medicare rate pressure ongoing

5. Geographic Footprint

• States served: 21+ states across Midwest, Mid-Atlantic, South, and Southwest
• Key states: Illinois (personal care legacy), Texas (Gentiva expansion), Indiana, Ohio, Missouri, North Carolina, Georgia
• New York: Divested personal care operations in FY2025 due to CDPAP regulatory restructuring [S1]
• Branch network: ~250+ local care centers (branches)

6. Customer Profile

• Age: Predominantly 65+; significant 75-85+ cohort
• Functional status: Require assistance with ≥2 ADLs; many have multiple chronic conditions
• Payor status: "Dual eligible" (Medicare + Medicaid) is the core; also Medicaid-only and Medicare-only
• Key characteristic: Sticky — consumers often stay with the same caregiver for years; high switching cost for patient

7. Competitive Positioning Summary

• Scale advantage: Top-5 independent personal care provider nationally post-Gentiva
• Technology: EVV compliance, scheduling algorithms — operational efficiency vs. smaller independents
• Managed care relationships: Long-term MCO contracts create revenue visibility
• Geographic density: Key in Illinois/Midwest; building density in South/Southwest via acquisitions

Source Index

• [S1] 10-K FY2025 (filed 2026-02-24) — SEC EDGAR
• [S2] Q1 2026 Earnings (8-K, May 2026) — Stocktitan.net summary
• [S3] StockAnalysis.com ADUS Overview — stockanalysis.com/stocks/adus/

---

source: coverage-next-full ticker: ADUS step: 04 title: Financial Quality & Adversarial Sweep generated: 2026-05-27

Step 04 — Financial Quality & Adversarial Research Sweep: Addus HomeCare Corporation (ADUS)

1. Financial Statement Quality Assessment

Revenue Recognition

• Method: Services delivered basis — revenue recognized when personal care hours are delivered, hospice days are served, or home health visits are completed [S1]
• Quality: HIGH. No complex arrangements, no percentage-of-completion, no deferred revenue structures. Service delivery is the single trigger.
• EVV verification: Electronic Visit Verification provides a real-time audit trail of care delivery, reducing billing disputes and fraud risk
• Adjustments needed: NONE significant. Revenue as reported is reliable.

Cost of Revenue

• Predominantly caregiver wages + benefits + workers' compensation insurance
• Payroll timing: Weekly/bi-weekly; no significant timing distortions
• Workers' comp: Self-insured to varying degrees by state; actuarial reserves reflect expected claims
• Quality: HIGH. Direct labor cost is straightforward to verify against payroll records.

Goodwill ($997M = 70% of total assets as of FY2025)

• Largest balance sheet item; reflects 20+ acquisitions over 10+ years
• Annual impairment testing required (ASC 350); no goodwill impairment charges recorded in FY2021-FY2025 [S1]
• Risk: If acquired businesses underperform (e.g., Gentiva integration fails), impairment charges could be material (~$100-300M non-cash write-down possible in adverse scenario)
• Assessment: Management has consistently delivered accretive acquisitions; goodwill level is elevated but supported by stable cash flows

Intangible Assets ($102M)

• Primarily customer relationships, non-compete agreements, and trade names acquired via M&A
• Amortized over useful lives (7-20 years typically for customer relationships)
• Annual amortization ~$15-17M; reduces GAAP earnings but not economic earnings
• Adjusted EBITDA addback: Amortization is legitimately added back to understand economic earnings

Deferred Revenue / Working Capital

• No significant deferred revenue
• Working capital: Accounts receivable ~$200-250M (Medicaid/Medicare — typically 45-90 day payment cycles)
• DSO (Days Sales Outstanding): ~60-75 days (typical for government payor); government is slower but reliable
• Quality: MEDIUM. Medicaid AR can be complex; some state-specific payment delays occur. No evidence of channel stuffing or premature revenue recognition.

Earnings Quality Score: B+ (High Quality)

• Core operations generate genuine cash flows: OCF/Net Income ratio ~1.15-1.2x (above 1.0 = good quality)
• SBC (~$18-20M/year) reduces cash compensation but is a real economic cost; GAAP earnings appropriately reflect this
• No significant one-time items manipulating reported results (integration costs disclosed separately as "non-cash" but cash is still deployed)

2. Adjusted Earnings vs. GAAP Reconciliation (FY2025)

Metric	GAAP	Adjustment	Adjusted
Net Income	$96M	—	$96M
Add: Amortization	—	+$16M	—
Add: SBC	—	+$18M	—
Add: D&A (ex-amortization)	—	+$5M	—
Less: Tax on addbacks	—	(~$9M)	—
Adjusted EBITDA	—	—	~$155M
Adjusted EPS (est.)	$5.22	+$1.30 adj.	~$6.40-6.50

Note: Management uses "Adjusted EPS" excluding amortization of acquired intangibles; Q1 2026 reported $1.62 adjusted EPS vs. $1.36 GAAP [S2]

3. Adversarial Research Sweep

Methodology: Searched for short-seller reports, regulatory investigations, class action lawsuits, whistleblower filings, and bearish institutional research. Transcript analysis not performed (coverage-next-full path).

Finding 1: No Active Short-Seller Reports

• No published short-seller thesis found (Hindenburg, Muddy Waters, Citron, etc.)
• Short interest: Modest; MarketBeat shows routine short interest without spike indicators [S3]
• Assessment: Clean — no organized short-side campaign targeting ADUS

Finding 2: New York CDPAP Divestiture (Regulatory Adverse Event)

• What happened: New York's Consumer Directed Personal Assistance Program (CDPAP) underwent restructuring in 2024-2025; state created a new fiscal intermediary (FI) model; ADUS determined its NY operations were no longer financially viable
• Impact: Divested NY personal care operations; revenue loss not disclosed but material enough to trigger divestiture; ADUS cited "changes and uncertainty in New York regarding the CDPAP" [S1]
• Assessment: RESOLVED — NY operations exited; no ongoing NY regulatory risk. Demonstrates that state regulatory changes CAN force business model exits. Bears cite this as evidence that reimbursement risk is real and not theoretical.

Finding 3: Medicaid Billing Compliance Risk

• Home health and hospice companies are perennial OIG targets for false claims and billing fraud
• ADUS 10-K discloses routine legal proceedings; no material OIG investigation or settlement found [S1]
• EVV mandate compliance reduces personal care billing abuse risk
• Assessment: LOW RISK — No material compliance issue identified; EVV reduces fraud exposure vs. pre-EVV era

Finding 4: OBBBA Medicaid Eligibility Restrictions

• "One Big Beautiful Bill Act" (Trump-era federal legislation) includes provisions limiting Medicaid eligibility (immigration status restrictions, work requirements)
• ADUS is exposed: If Medicaid rolls shrink, personal care census shrinks proportionally
• Assessment: ACTIVE RISK — Not a fraud concern but a legitimate business risk. Effect size uncertain; Congressional outcomes subject to change.

Finding 5: Insider Selling Pattern

• Multiple insiders sold shares over 2024-2025 via 10b5-1 plans [S4]
• No open-market buying documented in the same period
• Assessment: MILD YELLOW FLAG — Selling is routine (tax-driven) but absence of open-market buying reduces conviction signal from insiders. CEO's 1.6% stake ($16M at current price) is material but not dominant.

Finding 6: Goodwill Concentration / Acquisition Risk

• $997M goodwill on $1.43B revenue and $1.08B equity — balance sheet is goodwill-heavy
• Gentiva acquisition ($340M, closed 2024) is the largest single acquisition; integration still in progress [S1]
• Assessment: ONGOING RISK — Not a quality/fraud issue, but an execution risk. If Gentiva underperforms, non-cash impairment charges possible.

Finding 7: Labor Wage Pressure

• Caregiver wages are the dominant cost (67% of revenue); minimum wage increases in IL, TX, and other states create structural cost pressure
• Assessment: INDUSTRY-WIDE RISK — Not ADUS-specific; peers face identical dynamic. ADUS's scale and EVV efficiency somewhat mitigate vs. smaller players.

4. Financial Statement Flags Summary

Issue	Severity	Status
Revenue recognition	Low	Clean; service delivery basis
Goodwill impairment risk	Medium	Active; Gentiva integration key
NY CDPAP exit	Medium	Resolved; demonstrates state risk
Medicaid billing compliance	Low	No active investigation
Insider selling	Low	Routine 10b5-1; not conviction-driven
OBBBA Medicaid cuts	Medium-High	Active; legislative uncertainty
Short-seller activity	None	No organized short campaign

Overall Financial Quality Rating: B+ / Low Concern Core business generates real cash flows; accounting is straightforward; principal risks are regulatory/political, not accounting-based.

5. Quality Adjustments for Modeling

1. Use Adjusted EBITDA ($155M FY2025) for valuation; add back amortization of acquired intangibles ($16M)
2. Use Adjusted EPS for earnings power comparisons; adds back ~$0.90/share intangible amortization
3. Treat goodwill as a permanent asset for DCF purposes (no amortization under GAAP); test acquisition economics separately
4. FCF is the cleanest profitability measure: $104M FY2025 / $111M OCF after $8M CapEx

Source Index

• [S1] 10-K FY2025 (filed 2026-02-24) — SEC EDGAR
• [S2] Q1 2026 Earnings (8-K press release, May 2026) — via Stocktitan.net
• [S3] MarketBeat ADUS short interest — marketbeat.com/stocks/NASDAQ/ADUS/short-interest/
• [S4] SimplyWallSt — insider selling flag